April 12, 2026 06:23 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Legendary singer Asha Bhosle suffers cardiac arrest, hospitalised | Big boost to India–Mauritius ties: S. Jaishankar hands over 90 e-buses | Middle East tension: Iranian delegation arrives in Islamabad for major talks, 10,000 security personnel deployed | Ranveer Singh visits RSS HQ amid Dhurandhar 2 success, triggers speculation | ED raids ex-Bengal minister Partha Chatterjee; SSC scam resurfaces ahead of polls | Amit Shah promises UCC, ₹3,000 aid per month for women and youth in BJP’s Bengal manifesto | Nitish Kumar takes Rajya Sabha oath; power shift looms in Bihar | Sting video fallout: AIMIM snaps electoral ties with Humayun Kabir in Bengal | Israel says Hezbollah chief’s nephew-cum-secretary killed in Beirut strikes last night | Modi slams TMC on trade, fisheries at Haldia; vows 7th pay commission for govt employees

Singapore to begin human clinical trials on potential coronavirus treatment - Reports

| @indiablooms | Jun 10, 2020, at 04:26 pm

Moscow/Sputnik/UNI: Singapore will begin human clinical trials on a domestically developed treatment candidate for the coronavirus next week, media reported Wednesday.

According to the Singapore news outlet, The Strait Times, biotechnology company Tychan will administer the experimental treatment to 23 healthy individuals and monitor the results over six weeks.

The medication in question is the TY027, which was developed to specifically target Sars-Cov-2, the virus that causes COVID-19, the newspaper reported.

The medication is being studied for qualities of slowing the spread of the virus, speeding up recovery and even protecting against the infection, according to The Strait Times.

Tychan is one of the dozens of companies around the world racing to develop treatments and vaccines against the coronavirus, which has so far infected more than 7.3 million people and killed over 410,000. 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.